Mon panier

Monoclonal Anti-Mumps virus Fusion glycoprotein F0 Antibody, Human IgG1 (8F8) (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
RSF-MY2093-100ug
$415.00
RSF-MY2093-1mg (500ug X 2)
$2735.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Source

    Monoclonal Anti-Mumps virus Fusion glycoprotein F0 Antibody, Human IgG1 (8F8) is a recombinant chimeric monoclonal antibody expressed in HEK293, which combines the variable region of a mouse monoclonal antibody with human constant domain.

  • Antibody Type

    Recombinant Monoclonal

  • Clone

    8F8

  • Isotype

    Human IgG1, Kappa

  • Host Species

    Mouse

  • Reactivity

    Mumps virus (strain Miyahara vaccine) (MuV)

  • Immunogen

    Recombinant Mumps virus (strain Miyahara vaccine) (MuV) Fusion glycoprotein F0 is expressed from human 293 cells

  • Specificity

    Specifically recognizes Mumps virus Fusion glycoprotein F0 Protein.

  • Application

    Application
    Recommended Usage
    ELISA
    0.2-2 μg/mL
  • Purification

    Protein A purified / Protein G purified.

  • Aggregation

    Less than 10%, as determined by SEC-MALS.

  • Concentration

    Please refer to the Certificate of Analysis (CoA).

  • Form

    Lyophilized

  • Formulation

    Lyophilized from a 0.22 μm-filtered solution in PBS (pH 7.4), with trehalose as protectant.

    Please contact us for customized product forms or formulations.

  • Reconstitution

    Please refer to the Certificate of Analysis (CoA) for specific instructions.

  • Shipping

    Lyophilized product is shipped at ambient temperature.

  • Storage

    For long term storage, the product should be stored in a lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • Notices

    Product Specific Notices: For research use only.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • Bioactivity-ELISA

     Fusion glycoprotein F0 ELISA

    Immobilized Mumps virus (strain Miyahara vaccine) (MuV) Fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H4) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Mumps virus Fusion glycoprotein F0 Antibody, Human IgG1 (8F8) (Cat. No. RSF-MY2093) with a linear range of 0.06-2 ng/mL (QC tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

The two surface glycoproteins of the mumps virus are the hemagglutinin-neuraminidase (HN) and Fusion proteins. These glycoproteins are essential for viral entry to host cells, and the spread of newly formed virions. The mumps fusion protein (F) is a 538-amino acid, class one fusion surface glycoprotein. It is responsible for the membrane fusion of virus and host cell. The un-cleaved protein has three hydrophobic regions: an amino-terminal signal peptide, an amino terminal region of F1 and the carboxyl-terminal membrane domain. This protein starts as a precursor molecule (F0), and is then cleaved into the active protein by the recognition of a R-X-L/R-R motif by a host endoprotease (furin). The F protein contains two disulfide-linked polypeptides (F1 and F2).

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Respiratory syncytial virus F protein

  • Catégorie:

  • Nombre de médicaments répertoriés:

    3 Détails

  • Nombre de médicaments cliniques:

    7 Détails

  • Étape de développement la plus élevée:

    Approved

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte